Compiled by the editorial desk with reference to official FDA statements, public health data from the NIH, and reporting from Reuters, Forbes, and The New York Times.

The U.S. Food and Drug Administration has greenlit a new medication for amyotrophic lateral sclerosis (ALS), ending a 22-year drought in new treatment options. The drug, marketed as Radicava and chemically known as edaravone, was approved after clinical evidence suggested it could slow the relentless progression of the neurodegenerative disease.

ALS, a condition that gained widespread recognition through the Ice Bucket Challenge, affects an estimated 14,000 to 15,000 people in the United States and roughly 450,000 globally, according to the National Institutes of Health. Until now, the only FDA-approved treatment was Riluzole, which has been available since 1995. The approval of Radicava marks only the second time the agency has cleared a drug specifically for ALS.

Eric Bastings, a director at the FDA's Center for Drug Evaluation and Research, said in a statement that the agency moved quickly after learning about edaravone's use in Japan. "After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States," Bastings said. "This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option."

The disease, which attacks nerve cells in the brain and spinal cord, often leads to respiratory failure within three to five years of symptom onset in its most severe cases. While Radicava is not a cure, it offers a potential avenue to slow the disease's advance, providing patients with more time and hope.

Cost and Access Concerns

However, the new therapy comes with a substantial price tag. According to a Reuters report, each infusion of Radicava costs $1,086, and the recommended treatment involves 12 to 13 cycles, bringing the total to approximately $145,524 before any government discounts. The pharmaceutical company behind the drug, which was not named in the original report, is reportedly developing a co-payment assistance program to help patients manage the financial burden.

Despite the cost, the medical community has responded with cautious optimism. Dr. Nathan Staff, director of the ALS Clinic at the Mayo Clinic, told Forbes, "It's exciting. I expect many, if not all, of our patients will be lining up to try to get the medication."

The approval of Radicava represents a significant milestone for the ALS community, which has long awaited new therapeutic options. While the drug's high price may limit access for some, the development of a co-payment plan could alleviate some of the financial strain. As research continues, patients and clinicians alike are watching to see how this new treatment will impact the course of the disease.